← Leaderboards
Antino Recio Allen
Univ Of Arkansas For Med Scis
$1,861,157
Attributed
$2,217,211
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $687.1K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,217,211 · 2
By mechanism
R01$1,505,103 · 1
T32$712,108 · 1
Top collaborators
- Billy R Thomas2 shared
Most similar at Univ Of Arkansas For Med Scis
Same institution · by research overlap
- Maria Jose Almeida$5,489,226
- Charles A O'Brien$15,608,722
- Gal Shafirstein$8,387,565
- Nukhet Aykin-Burns$1,783,016
- Amanda Stolarz$1,938,006
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectCell InjuryAmericanAnimal ModelAnimalsAdjuvant TherapyAntioxidantsApoptosisArchitectureBehavioralBiochemistryBioenergeticsAnti-Inflammatory AgentsAftercareBrainBrain InjuriesBrain TissueBreast Cancer ModelBreast Cancer TreatmentCancer CellCancer DiagnosisCancer SurvivorCancer TherapyCell Respiration
Grant awards (6)
Initiative for Maximizing Student Development(IMSD)$332,317
T32 · FY2025 · GM
Initiative for Maximizing Student Development(IMSD)$379,791
T32 · FY2024 · GM
MnBuOE as a Novel Chemosensitizer for Breast Cancer and Neuroprotector$307,350
R01 · FY2024 · CA · contact PI
MnBuOE as a Novel Chemosensitizer for Breast Cancer and Neuroprotector$396,320
R01 · FY2023 · CA · contact PI
MnBuOE as a Novel Chemosensitizer for Breast Cancer and Neuroprotector$384,508
R01 · FY2022 · CA · contact PI
MnBuOE as a Novel Chemosensitizer for Breast Cancer and Neuroprotector$416,925
R01 · FY2021 · CA · contact PI